๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Shenzhen
Clinical trial register · China

Clinical Trials in Shenzhen, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Shenzhen Geno-Immune Medical Institute43 Beijing Biotech32 Sun Yat-sen University23 Bristol-Myers Squibb19 Shenzhen University General Hospital11
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Shenzhen

576 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
A Clinical Study to Evaluate the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamics of Inhaled H057 in the Treatment of Acute Exacerbations of Bronchiectasis
NCT06958861Acute Exacerbations of Bronchiectasis
Shanghai Huilun Pharmaceutical Co., Ltd.
Phase 2
180
Fuyang, Hefei, Fuzhou, Guangzhou, Shenzhen, Baise City, Shijiazhuang, Nanyang
2025-05
Recruiting
A Study of TQB3473 Tablets Compared to Placebo in the Treatment of Adult Primary Immune Thrombocytopenia
NCT06900920Primary Immune Thrombocytopenia
DrugTQB3473
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 3
199
Hefei, Wuhu, Beijing, Chongqing, Lanzhou, Guangzhou, Shenzhen, Zhanjiang
2025-04-30
Recruiting
Clinical Study on the Efficacy and Safety of TNTL in the Treatment of Non-proliferative Diabetic Retinopathy
NCT06817265Non-Proliferative Diabetic Retinopathy
Beletalent (Zhuhai) Pharmaceutical Co., Ltd
Phase 3
360
Xuancheng, Beijing, Guangzhou, Shenzhen, Zhuhai, Guiyang, Shijiazhuang, Kaifeng
2025-04-29
Recruiting
Clinical Studies for the Treatment of Advanced Solid Tumors
NCT06825494Advanced Solid Tumor
DrugsLM-108·Penpulimab·Oxaliplatin·Capecitabine
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
194
Hefei, Beijing, Fuzhou, Lanzhou, Wuwei, Shenzhen, Nanning, Tangshan
2025-04-08
Recruiting
A Study of Treatment-Related Toxicities and Quality of Life After Local Therapy in Chinese Breast Cancer Patients
NCT07010939Breast Neoplasms, Quality of Life (QOL), Toxicities, Breast Diseases
FangYi
Observational
3,000
Beijing, Shenzhen, Taiyuan
2025-04-07
Recruiting
A Phase II Study to Evaluate HLX43 in Subjects With Recurrent/Metastatic Nasopharyngeal Carcinoma Failed or Intolerance to Second-line Therapy
NCT06839066Nasopharyngeal Carcinoma (NPC)
DrugsHLX43 3·HLX43 2·HLX43 1
Shanghai Henlius Biotech
Phase 2
70
Fuzhou, Dongguan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2025-04-02
Active, closed
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045Hemophilia
Jiangsu BioJeTay Biotechnology Co., Ltd.
Phase 3
40
Hefei, Lanzhou, Guangzhou, Shenzhen, Nanning, Tangshan, Harbin, Zhengzhou
2025-03-26
Recruiting
This Study is a FIH Study Which is Required to Understand the PK Characteristics, MTD, RP2D and Safety Profile.
NCT06756451Hematologic Malignancies
Nanjing RegeneCore Biotech Co., Ltd.
Phase 1
71
Hefei, Guangzhou, Shenzhen, Guilin, Nanning, Baoding, Tangshan, Zhengzhou
2025-03-25
Recruiting
The Effect of VitC on IVF Outcome of DOR Patients
NCT06794047Diminished Ovarian Reserve, IVF Outcomes
Peking University Third Hospital
Not applicable
1,100
Beijing, Shijiazhuang, Yinchuan, Xiโ€™an, Shenzhen
2025-03-17
Recruiting
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines
NCT06671496Psoriatic Arthritis
DrugZasocitinib
Takeda
Phase 3
600
Bengbu, Beijing, Xiamen, Guangzhou, Shenzhen, Luoyang, Wuhan, Zhuzhou
2025-03-10
Recruiting
Capsule Gastric Endoscopy for Gastric Disease Screening in Simulated Home Scenarios
NCT06848400Gastric Lesion, Gastritis, Upper Gastrointestinal Bleeding (UGIB), Gastric Dysplasia
Nanfang Hospital, Southern Medical University
Not applicable
482
Guangzhou, Shaoguan, Shenzhen, Zhuhai, Wuxi, Ganzhou, Mianyang
2025-03-03
By invitation
WeChat-Based Digital Therapy to Improve Fluid Intake in Kidney Stone Patients: Study Protocol
NCT06990672Urinary Calculi, Postoperative Care, Chronic Disease Prevention
The University of Hong Kong
Not applicable
148
Shenzhen
2025-03-01
Not yet open
A Clinical Trial to Evaluate the Efficacy and Safety of Methoxyethyl Etomidate Hydrochloride for Sedation/Anesthesia During Gastroscopy/Colonoscopy
NCT06858852Gastroscopy, Colonoscopy
Ahon Pharmaceutical Co., Ltd.
Phase 3
270
Beijing, Shenzhen, Chengdu, Guangyuan, Yibin
2025-03
Not yet open
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931Systemic Lupus Erythematosus
DrugTQB3702
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
120
Bengbu, Hefei, Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Langfang
2025-03
Recruiting
To Evaluate the Safety and Efficacy of a Single-Use IVUS Ablation for Primary Hypertension
NCT07051811Essential Hypertension
Lepu Medical Technology (Beijing) Co., Ltd.
Not applicable
213
Beijing, Chongqing, Xiamen, Lanzhou, Shenzhen, Zhengzhou, Hohhot, Yinchuan
2025-02-25
Recruiting
Effects of Inspiratory Muscle Training on Stroke Rehabilitation Outcomes
NCT06640101Stroke
Hong Kong Metropolitan University
Not applicable
84
Shenzhen
2025-02-21
Active, closed
Toripalimab vs. Placebo Wtih GP Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma
NCT06712888Nasopharyngeal Carcinoma (NPC)
Sun Yat-sen University
Phase 3
466
Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning, Guiyang, Changsha, Chengdu
2025-02-17
Recruiting
RAPART in Locally Advanced Non-small Cell Lung Cancer Patients
NCT07164885Locally Advanced Non-small Cell Lung Cancer
Capital Medical University
Not applicable
911
Shenzhen
2025-02-17
Recruiting
A Study to Test Whether Spesolimab Helps People With a Skin Condition Called Pyoderma Gangrenosum
NCT06624670Pyoderma Gangrenosum
DrugsSpesolimab·Prednisolone·Prednisone
LEO Pharma
Phase 3
90
Beijing, Changchun, Changsha, Chengdu, Hangzhou, Jinan, Shanghai, Shenzhen
2025-02-05
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis
NCT06767540Atopic Dermatitis
Akeso
Phase 3
198
Wuhu, Beijing, Chongqing, Dongguan, Guangzhou, Jiangmen, Shenzhen, Zhuhai
2025-01-23
Recruiting
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
NCT06760039Diffuse Large B-Cell Lymphoma
DrugR-Chop
Sun Yat-sen University
Phase 1/2
112
Fuzhou, Lanzhou, Guangzhou, Shenzhen, Zhuhai, Guilin, Ganzhou, Nanchang
2025-01-10
Recruiting
Fluid Responsiveness and Venous Congestion Evolution During Volume Expansion
NCT06772038Hemodynamic, Fluid Responsiveness, Venous Congestion, Fluid Challenge
Bicetre Hospital
Observational
64
Guangzhou, Shenzhen
2025-01-05
Recruiting
The Association Between Core Temperature and Health
NCT06432491Body Temperature Changes, Body Composition, Aging
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
36
Shenzhen
2025-01-01
By invitation
Serum IGF1 on Female HFpEF Patients
NCT07015554HFpEF - Heart Failure With Preserved Ejection Fraction
The University of Hong Kong-Shenzhen Hospital
Observational
120
Shenzhen
2025-01-01
By invitation
The Correlation Between Serum PRMT5 Level and Cardiac Ultrasound Indicators in Patients With Heart Failure
NCT07050706Heart Failure, Systolic
The University of Hong Kong-Shenzhen Hospital
Observational
50
Shenzhen
2025-01-01
Recruiting
Efficacy and Safety of CD19/CD20 CAR/TRuC-T in Relapsed/Refractory B-Cell Lymphoma
NCT07508605Relapsed/Refractory B-cell Lymphoma
Shenzhen University General Hospital
Phase 1/2
20
Shenzhen
2025-01-01
Recruiting
Glycemic Improvement With Team, Technology, Education and Peer Resources in Type 1 Diabetes-GLITTER Study
NCT07097805Type 1 Diabetes (T1D)
Second Xiangya Hospital of Central South University
Not applicable
3,000
Beijing, Guangzhou, Shenzhen, Luoyang, Changsha, Nanjing, Shenyang, Chengdu
2025-01-01
Not yet open
A Clinical Study of AK120 in Adolescents With Moderate-to-severe Atopic Dermatitis (AD)
NCT06756126Atopic Dermatitis
Akeso
Phase 2
24
Dongguan, Guangzhou, Shenzhen, Changsha, Ningbo
2024-12-30
Recruiting
Study With Omecamtiv Mecarbil (CK-1827452) to Treat Chronic Heart Failure With Severely Reduced Ejection Fraction
NCT06736574Heart Failure, Heart Failure With Reduced Ejection Fraction
Cytokinetics
Phase 3
1,800
Beijing, Lanzhou, Guangzhou, Shenzhen, Nanning, Luoyang, Changsha, Chifeng
2024-12-19
Recruiting
Spatially Fractionated Radiotherapy for Tumor Treatment
NCT07774819Radiotherapy-Induced Immune Priming
Xu Zhi-yuan
Phase 1/2
126
Shenzhen
2024-12-19
Recruiting
Clinical Trial of TQB3002 in Patients With Advanced Cancers
NCT06662760Advanced Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1
150
Guangzhou, Shenzhen, Zhengzhou, Nanjing, Nanchang, Shanghai, Xiโ€™an, Chengdu
2024-12-09
Recruiting
Long-term Follow-up Study of BRL-101 for TDT
NCT06298630Thalassemia, Beta
Bioray Laboratories
Observational
45
Guangzhou, Shenzhen, Nanning, Changsha, Tianjin, Guangxi
2024-12-08
Active, closed
Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection
NCT06706310Chronic Hepatitis B
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
116
Chongqing, Guangzhou, Shenzhen, Liuzhou, Wuhan, Changsha, Wuxi, Changchun
2024-12-04
Active, closed
Postural Decoding for Post-Stroke Shoulder Pain: A RCT.
NCT06763796Stroke; Sequelae
Shenzhen Baoan District Fuyong People's Hospital
Not applicable
48
Shenzhen
2024-12-01
By invitation
Risk Model for Metastasis Detection of Neuroblastoma
NCT06703944Neuroblastoma (NB), Prognosis, Bone Marrow Metastasis, Bone Metastases
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Observational
500
Shanghai, Hangzhou, Shenzhen
2024-12-01
Not yet open
Exploration of the Efficacy and Mechanisms of Lymphaticovenous Anastomosis in the Treatment of Alzheimer's Disease
NCT06706947Alzheimer's Disease (AD)
Luo Xinxin
Not applicable
20
Shenzhen
2024-12-01
Not yet open
Evaluating the Analgesic Efficacy of Oxycodone Hydrochloride in Pediatric Laparoscopic Cryptorchidism Surgery
NCT06665048Anesthesia, Oxycodone, Analgesia, Postoperative
Shantou University Medical College
Not applicable
162
Shenzhen
2024-12-01
Recruiting
Inhaling Penehyclidine to Prevent Perioperative Respiratory Adverse Events in Children at Risk Undergoing Sevoflurane Anesthesia
NCT06624696Respiratory Hypersensitivity, Perioperative Respiratory Adverse Events, Anticholinergics, Inhalation Therapy; Complications
Sun Yat-sen University
Phase 4
204
Guangzhou, Shenzhen
2024-11-12
Recruiting
IMM01+Azacitidine VS Placebo +Azacitidine in Patients With Newly Diagnosed Chronic Myelomonocytic Leukemia (CMML1-2)
NCT06647862Chronic Myelomonocytic Leukemia
DrugAzacitidine
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
Phase 3
170
Hefei, Beijing, Chongqing, Lanzhou, Nanning, Guangzhou, Shenzhen, Zhujiang
2024-11-11
Recruiting
Orelabrutinib in Combination with R-CHOP for CD5-positive DLBCL Patients๏ผˆRocket Trial๏ผ‰
NCT06647940Diffuse Large B Cell Lymphoma (DLBCL)
DrugsR-CHOP Protocol·Orelabrutinib
Sun Yat-sen University
Phase 2
39
Guangzhou, Lanzhou, Dongguan, Shantou, Shenzhen, Zhaoqing, Zhuhai
2024-11-01
Not yet open
Identification Of High-risk Coronary Plaques By Multimodal Intravascular Imaging
NCT06681155Coronary Arterial Disease (CAD), Acute Coronary Syndromes
Chinese PLA General Hospital
Observational
500
Shenzhen, Wuhan, Changchun, Xi'an, รœrรผmqi, Hangzhou, Beijing
2024-11
Not yet open
Minimal Residual Disease Guiding Adjuvant Therapy in Stage I NSCLC
NCT06709274Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials
Not applicable
342
Dongguan, Foshan, Guangzhou, Shenzhen, Nanning, Guiyang, Wuhan, Changsha
2024-11
Recruiting
A Study to Evaluate the Efficacy and Safety of Combination Therapy of BRII-179, BRII-835 and PEG-IFNฮฑ in Participants With Chronic Hepatitis B Virus (HBV) Infection (ENHANCE)
NCT06650852Chronic Hepatitis B Virus (HBV) Infection
DrugsPEG-IFNฮฑ·Elebsiran
Brii Biosciences Limited
Phase 2
250
Beijing, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-10-31
Not yet open
A Study on the Safety and Efficacy of BST08 in Treating Advanced Non-Small Cell Lung Cancer
NCT06643910Non-small Cell Lung Cancer
BioSyngen Pte Ltd
Not applicable
12
Shenzhen
2024-10-24
Recruiting
The Effects of the Control Strategies of Wearable Lower Limb Rehabilitation Robots
NCT07037849Stroke, Gait Training, Gait Disorders
Eighth Affiliated Hospital, Sun Yat-sen University
Not applicable
10
Shenzhen
2024-10-23
Recruiting
The Effect of Coffee on People with High Intensity Exercise and the Characteristics of Caffeine Metabolism
NCT06712667Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
24
Shenzhen
2024-10-23
Recruiting
The Effect of Coffee on Energy Expenditure and Caffeine Metabolism
NCT06712511Healthy
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
60
Shenzhen
2024-10-23
Recruiting
INTERSTELLAR - International Study Evaluating Lupus Outcomes After Anifrolumab Real World Use
NCT06314282Systemic Lupus Erythematosus (SLE)
AstraZeneca
Observational
200
Guangzhou, Hong Kong, Shenzhen, Zhongshan, Zhuhai
2024-10-22
Active, closed
Phase 3 Study of Vorasidenib (S095032/AG-881) in Asian Participants With Residual or Recurrent Grade 2 Glioma With an IDH1 orIDH2 Mutation
NCT06780930Residual or Recurrent Grade 2 IDH Mutant Glioma
DrugVorasidenib
Servier
Phase 3
57
Shenzhen, Chengdu, Beijing, Shanghai, Xi'an
2024-10-18
Recruiting
Long-term Impact of Inhaled Tobramycin for Pseudomonas Aeruginosa Eradication in Bronchiectasis (ERASE II)
NCT06760273Bronchiectasis Adult
Shanghai Pulmonary Hospital, Shanghai, China
Observational
364
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Shenzhen, Zhanjiang, Nanning
2024-10-16
Recruiting
Efficacy of Self-expandable and Balloon-expandable Valves in Patients With Ascending Aortic Dilation
NCT06743568Aortic Stenosis, Ascending Aortic Dilatation
China National Center for Cardiovascular Diseases
Not applicable
100
Beijing, Shenzhen, Kunming
2024-10-15
Recruiting
Efficacy Evaluation Study of BAT5906 and Lucentisยฎ in Patients With Diabetic Macular Edema
NCT07515079Diabetic Macular Edema (DME)
DrugLucentis
Bio-Thera Solutions
Phase 3
406
Beijing, Chongqing, Lanzhou, Guangzhou, Shantou, Shenzhen, Nanning, Zunyi
2024-10-09
Active, closed
To Evaluate the Phase III Clinical Trial of TQH2722 Injection in the Treatment of Moderate to Severe Atopic Dermatitis
NCT06552520Atopic Dermatitis
DrugTQH2722
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 3
500
Bengbu, Tongling, Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen
2024-10-08
Not yet open
Application of Nanopore Adaptive Sequencing
NCT06542042Liver Transplant Infection
Shenzhen Third People's Hospital
Observational
100
Shenzhen
2024-10-01
Active, closed
Study on the Relationship Between Indoor Environment, Use of Personal Disinfection Products, and Human Health
NCT06637826Healthy
National Natural Science Foundation of China
Phase EARLY_PHASE1
64
Shenzhen
2024-10-01
Recruiting
Peripheral Scoring Drug-coated Balloon in the Treatment of Hemodialysis Arteriovenous Fistula Stenosis
NCT06422845Arteriovenous Fistula Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
328
Hefei, Beijing, Chongqing, Guanzhou, Huizhou, Shenzhen, Liuzhou, Nanning
2024-09-30
Recruiting
A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4)
NCT06585787Alzheimer Disease
DrugKarXT
Karuna Therapeutics, Inc., a Bristol Myers Squibb company
Phase 3
406
Beijing, Chongqing, Guangzhou, Shenzhen, Nanjing, Zhenjiang, Xi'an, Shanghai
2024-09-26
Recruiting
Remote Ischemic Conditioning for Acute Ischemic Stroke Treated With Mechanical Thrombectomy๏ผˆRECAST-MT๏ผ‰
NCT06559241Acute Ischemic Stroke, Anterior Circulation Brain Infarction
Capital Medical University
Phase 3
2,105
Suzhou, Taihe Chengguanzhen, Tongling, Beijing, Fuzhou, Zhangzhou, Shenzhen, Nanning
2024-09-23
Not yet open
To Evaluate Recombinant Human Follicle Stimulating Hormone-CTP Fusion Protein Injection or Placebo Combined With Chorionic Gonadotropin for Injection
NCT06561594Idiopathic Hypogonadotropic Hypogonadism
Changchun GeneScience Pharmaceutical Co., Ltd.
Phase 3
60
Hefei, Beijing, Guangzhou, Shenzhen, Zhengzhou, Wuhan, Nanjing, Nanchang
2024-09-20
Active, closed
A Study of Obexelimab in Patients With Systemic Lupus Erythematosus
NCT06559163Systemic Lupus Erythematosus
DrugObexelimab
Zenas BioPharma (USA), LLC
Phase 2
190
Hefei, Beijing, Guangzhou, Shenzhen, Shijiazhuang, Nanchang, Pudong, Shanghai
2024-09-17
Recruiting
A Clinical Study on Recombinant Botulinum Toxin Type A (YY001) for Injection in The Treatment of Upper Limb Spasticity in Adults
NCT06783114Upper Limb Spasticity
Chongqing Claruvis Pharmaceutical Co., Ltd.
Phase 2/3
254
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Kaifeng, Wuhan, Huai'an
2024-09-14
Recruiting
Optimization of Keverprazan-amoxicillin Dual Therapy for Eradicating Helicobacter Pylori Infection
NCT06734260Helicobacter Pylori Eradication Rate
DrugAmoxicillin
Eighth Affiliated Hospital, Sun Yat-sen University
Phase 3
477
Guangzhou, Puning, Shenzhen, Xiangyang
2024-09-10
Recruiting
A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR2001 Injection
NCT06635798Tetanus
DrugHTIG
Genrix (Shanghai) Biopharmaceutical Co., Ltd.
Phase 3
582
Hefei, Beijing, Guangzhou, Shenzhen, Liuzhou, Zunyi, Wuhan, Hengyang
2024-09-03
Recruiting
Oral Fecal Microbiota Transplantation in Advanced Hepatocellular Carcinoma After Progression on ICI-TKI Therapy
NCT06563947Advanced Hepatocellular Carcinoma
DrugFecal Microbiota Transplantation
Xu Yong, MD
Phase 2
30
Shenzhen
2024-09-03
Recruiting
Irinotecan Liposome in Combination With Capecitabine
NCT06578052Pancreatic Cancer
Junjie Hang
Not applicable
20
Shenzhen
2024-08-28
Recruiting
Randomized Study of ABC-14 Regimen Compared With "3+7" Standard Induction Therapy or AB-14 for ND AML
NCT06451861Acute Myeloid Leukemia
DrugsCytarabine·Chidamide·Azacitidine·Venetoclax
Guangdong Provincial People's Hospital
Phase 2
240
Dongguan, Foshan, Guangzhou, Shenzhen, Zhanjiang, Zhuhai, Haikou
2024-08-21
Recruiting
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among Older People Living With HIV
NCT06560840Hiv, Atherosclerosis, Diet, Healthy
Fudan University
Not applicable
110
Shenzhen
2024-08-20
Recruiting
A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
NCT06461897Atopic Dermatitis
DrugsDupilumab·Upadacitinib
AbbVie
Phase 3
675
Beijing, Yuzhong District, Xiamen, Shenzhen, Zhengzhou, Changsha, Dalian, Chengdu
2024-08-19
Recruiting
Scoring Balloon and High Pressure Balloon in the Treatment of Arteriovenous Graft Stenosis
NCT06503692Arteriovenous Graft Stenosis
DK Medical Technology (Suzhou) Co., Ltd.
Not applicable
140
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Shanghai
2024-08-13
Recruiting
JAB-21822 Combined With JAB-3312 Compared SOC in the First Line for Treatment of Advanced Non-small Cell Lung Cancer With KRAS p.G12C Mutation
NCT06416410Advanced Non-squamous Non-small-cell Lung Cancer, Metastatic Non-squamous Non Small Cell Lung Cancer
DrugsJAB-3312·Glecirasib·Pemetrexed·Tislelizumab
Allist Pharmaceuticals, Inc.
Phase 3
392
Hefei, Beijing, Fuzhou, Guangzhou, Shenzhen, Nanning, Cangzhou, Haerbin
2024-08-07
Recruiting
A Clinical Trial of TQB2102 for Injection in Non-small Cell Lung Cancer With HER2 Gene Abnormality
NCT06496490Non-Small Cell Lung Cancer
DrugsTQB2102·Etoposide
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 2
270
Fuzhou, Foshan, Guangzhou, Jiangmen, Shenzhen, Nanning, Zunyi, Harbin
2024-08-06
Active, closed
Study to Investigate the Efficacy and Safety of Regimens Containing BRII-179, BRII-835, and PEG-IFNฮฑ Treating Chronic Hepatitis B Virus (HBV) Infection (ENRICH)
NCT06491563For Treatment of Chronic Hepatitis B Virus Infection
Brii Biosciences Limited
Phase 2
150
Beijing, Xiamen, Foshan, Guangzhou, Shenzhen, Shanghai, Chengdu, Hangzhou
2024-08-06
Active, closed
Open-label Extension Study of Enlicitide Decanoate (MK-0616/Enlicitide Oral PCSK9 Inhibitor) in Adults With Hypercholesterolemia (MK-0616-019) CORALreef Extension
NCT06492291Hypercholesterolemia
DrugEnlicitide Decanoate
Merck Sharp & Dohme LLC
Phase 3
3,000
Beijing, Chongqing, Guangzhou, Huizhou, Shenzhen, Jingzhou, Wuhan, Changsha
2024-08-05
Recruiting
A Phase Ib/II Study of Adebrelimab in Combination with Capecitabine and Oxaliplatin in Cancer
NCT06776770Gastric Cancer
DrugAdebrelimab
Cancer Hospital Chinese Academy of Medical Science, Shenzhen Center
Phase 1/2
52
Shenzhen
2024-08-03
Recruiting
The Influence of Climate and Air Pollution on Physical Activity of Chinese People in Shenyang and Shenzhen
NCT07523659Physical Activity, Climate, Air Pollution
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Observational
124
Shenzhen, Shenyang
2024-08-01
Active, closed
A Phase III Study to Investigate Efficacy, Safety and Tolerability of Iptacopan Compared With Placebo in Participants Aged 18 to 85 Years With gMG.
NCT06517758Generalized Myasthenia Gravis
DrugIptacopan
Novartis Pharmaceuticals
Phase 3
146
Hefei, Guangzhou, Shenzhen, Shijiazhuang, Changsha, Suzhou, Xi'an, Xianyang
2024-07-31
Recruiting
CPVI With Modified Linear Ablation Versus CPVI in Patients With Long-standing Persistent Atrial Fibrillation (SINUS)
NCT06516822Long-standing Persistent Atrial Fibrillation, Ablation
The First Affiliated Hospital with Nanjing Medical University
Not applicable
320
Beijing, Guangzhou, Shenzhen, Zhengzhou, Nanjing, Dalian, Jinan, Xiโ€™an
2024-07-31
Recruiting
Efficacy and Safety of Prunella Oral Liquid in the Treatment of Thyroid Nodules
NCT06423235Thyroid Nodule
Xintian Pharmaceutical
Phase 4
234
Chongqing, Xiamen, Guangzhou, Shenzhen, Shunde, Wuhan, Nanjing, Xuzhou
2024-07-30
Recruiting
PulseSelectโ„ข PFA Global Registry
NCT06393920Atrial Fibrillation
Medtronic Cardiac Ablation Solutions
Observational
1,950
Beijing, Fuzhou, Harbin, Kunming, Nanjing, Shanghai, Shenzhen, รœrรผmqi
2024-07-23
By invitation
Cross Validation of Body Composition Measurement
NCT06453564Body Composition
John R. Speakman
Observational
30
Shenzhen
2024-07-19
Recruiting
The Study is an Observational Post-market Follow-up Program to Evaluate Long Term (5 Years) Safety of Mentor Breast Implants in Chinese Population
NCT06510205Breast Augmentation, Mammaplasty
Johnson & Johnson Medical (Shanghai) Ltd.
Observational
6,111
Chengdu, Kunming, Shenzhen
2024-07-14
Recruiting
Neoadjuvant vs Adjuvant in Locally Advanced Recurrent NPC
NCT06235203Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
154
Shanghai, Fuzhou, Nanning, Shenzhen
2024-07-09
Active, closed
Intravascular Imaging Study of the Effect of Inclisiran on Plaque in Patients With Acute Myocardial Infarction
NCT06372925Plaque, Atherosclerotic
DrugsInclisiran·Atorvastatin
Novartis Pharmaceuticals
Phase 4
318
Hefei, Fuzhou, Guangzhou, Shenzhen, Zunyi, Harbin, Zhengzhou, Wuhan
2024-07-09
Recruiting
Adjuvant vs Surgery Only in Early-stage Recurrent NPC
NCT06228079Recurrent Nasopharyngeal Carcinoma
Eye & ENT Hospital of Fudan University
Phase 3
176
Shanghai, Fuzhou, Nanning, Shenzhen
2024-06-25
Recruiting
GP Plus Adebrelimab Versus GP Neoadjuvant Chemotherapy for Nasopharyngeal Carcinoma
NCT06455410Nasopharyngeal Carcinoma
DrugsConcurrent chemoradiotherapy·CCRT·GP·Adebrelimab
Sun Yat-sen University
Phase 2
216
Foshan, Guangzhou, Liuzhou, Nanning, Shantou, Shenzhen, Zhangjiang
2024-06-18
Recruiting
Evaluating Safety and Efficacy of Lentiviral-transduced CD34+ HSCs in ฮ’-thalassaemia Patients.
NCT06655662ฮ’-thalassemia
Shenzhen Hemogen
Phase 1
8
Guangxi, Shenzhen
2024-06-12
Recruiting
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
NCT06399185Urinary Catheter, Catheter-related Bladder Discomfort, Dexmedetomidine, Esketamine
Peking University First Hospital
Phase 4
1,740
Beijing, Shenzhen
2024-06-06
Not yet open
Henagliflozin's Impact on Prediabetes Remission
NCT06448130PreDiabetes, Prediabetic State, Type 2 Diabetes, Glucose Metabolism Disorders
DrugHenagliflozin
Shandong Provincial Hospital
Phase 4
984
Chuzhou, Hefei, Fuzhou, Lanzhou, Foshan, Guangzhou, Guanzhou, Shenzhen
2024-06
Recruiting
Effects of Intraoperative Targeted Temperature Management on Incidence of Postoperative Delirium and Long-term Survival
NCT06256354Cancer Surgery, Intraoperative Hypothermia, Targeted Temperature Management, Postoperative Delirium
Peking University First Hospital
Not applicable
3,992
Chizhou, Hefei, Maโ€™anshan, Beijing, Chongqing, Shenzhen, Shijiazhuang, Harbin
2024-05-29
Recruiting
Treatment of Vasospasm of Aneurysmal Subarachnoid Hemorrhage With Intrathecal Nicardipine - FAST-IT Trial
NCT06329635Aneurysmal Subarachnoid Hemorrhage, Vasospasm
DrugNicardipine
The Affiliated Hospital Of Guizhou Medical University
Not applicable
396
Hefei, Beijing, Chongqing, Guangzhou, Shenzhen, Nanning, Guiyang, Kaili
2024-05-27
Recruiting
Sources and Mechanisms of Energy Compensation
NCT06432517Energy Expenditure, Exercise, Energy Intake, Food Preferences
Shenzhen Institutes of Advanced Technology ,Chinese Academy of Sciences
Not applicable
81
Shenzhen
2024-05-20
Active, closed
A Study to Assess the Effectiveness and Safety of Ozanimod in Chinese Adults With Relapsing Multiple Sclerosis
NCT06396039Relapsing Multiple Sclerosis
Bristol-Myers Squibb
Phase 4
84
Beijing, Guangzhou, Shenzhen, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Nanchang
2024-05-15
Active, closed
Phase 3 Study of ALXN1850 in Treatment-Naรฏve Pediatric Participants With HPP
NCT06079359Hypophosphatasia
DrugALXN1850
Alexion Pharmaceuticals, Inc.
Phase 3
30
Beijing, Guangzhou, Shanghai, Shenzhen
2024-05-14
Recruiting
Efficacy and Safety of Avatrombopag in the Treatment of Thrombocytopenia After Haplo-HSCT
NCT06202625Thrombocytopenia, Stem Cell Transplant Complications
Peking University People's Hospital
Phase 2/3
142
Beijing, Guangzhou, Shenzhen, Harbin, Zhengzhou, Wuhan, Changsha, Nanchang
2024-05-13
Recruiting
A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic Cancer
NCT06361888Metastatic Pancreatic Cancer
Hutchmed
Phase 2/3
502
Hefei, Beijing, Chongqing, Fuzhou, Xiamen, Shenzhen, Nanning, Guandong
2024-05-08
Active, closed
A Study of Lebrikizumab (LY3650150) With/Without Topical Corticosteroid Treatment in Participants With Moderate-to-Severe Atopic Dermatitis
NCT06280716Atopic Dermatitis
DrugLebrikizumab
Eli Lilly and Company
Phase 3
301
Wuhu, Beijing, Chongqing, Xiamen, Guangzhou, Shenzhen, Haikou, Shijiazhuang
2024-04-24
Recruiting
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151Ovarian Cancer Recurrent, Endometrial Cancer Recurrent, Cervical Cancer Recurrent
Sun Yat-sen University
Observational
200
Guangzhou, Shenzhen
2024-04-24
Active, closed
Study to Evaluate Efficacy and Safety of Romosozumab Compared With Bisphosphonates in Children and Adolescents With Osteogenesis Imperfecta
NCT05972551Osteogenesis Imperfecta
DrugsBisphosphonate·Romosozumab
Amgen
Phase 3
111
Beijing, Shenzhen, Wuhan, Suzhou, Changchun, Jinan, Chengdu, Shanghai
2024-04-22
Recruiting
Efficacy and Safety of CD19-CAR.p40-T in Patients With Relapsed/Refractory CD19-Positive Hematologic Malignancies
NCT07584889B Cell Lymphoma, Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia
Shenzhen University General Hospital
Phase 1/2
10
Shenzhen
2024-04-20
Recruiting
Efficacy and Safety of Fecal Microbiota Transplantation (FMT) in Reducing Recurrence of Colorectal Adenoma (CRA)
NCT06205862Fecal Microbiota Transplantation, Colorectal Adenoma, Gastrointestinal Microbiome
Shenzhen Hospital of Southern Medical University
Phase 2
466
Guangzhou, Shenzhen, Shunde
2024-04-09
Rows per page Showing 301–400 of 576
Previous 2 3 4 5 6 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 25 September 2026. https://priyalifescience.com/clinical-trials-china/city/shenzhen?page=4

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 576 of those studies with a site in Shenzhen.

How many clinical trials are recruiting in Shenzhen?

337 of the 576 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 115 have not yet opened recruitment, 109 are active but closed to new participants, and 15 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.